Last reviewed · How we verify
NTRK fusion gene-positive advanced or recurrent solid tumors
Approved treatments
- Vitrakvi · Bayer
Vitrakvi works by blocking the activity of a specific protein called the nerve growth factor receptor.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- NTRK fusion gene-positive advanced or recurrent solid tumors patent landscape — cliff calendar, originator estates, attackable patents
- NTRK fusion gene-positive advanced or recurrent solid tumors treatment landscape brief
- NTRK fusion gene-positive advanced or recurrent solid tumors treatment updates RSS
Frequently asked questions about NTRK fusion gene-positive advanced or recurrent solid tumors
What drugs treat NTRK fusion gene-positive advanced or recurrent solid tumors?
Tracked treatments include Vitrakvi.
What is the treatment for NTRK fusion gene-positive advanced or recurrent solid tumors?
Standard treatment for NTRK fusion gene-positive advanced or recurrent solid tumors includes Vitrakvi. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: NTRK fusion gene-positive advanced or recurrent solid tumors patent cliff · NTRK fusion gene-positive advanced or recurrent solid tumors CI report
- Treatment: Vitrakvi · Bayer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing